The FDA recently released a new guidance document to assist sponsors in the clinical development of drugs and biological products for the treatment of ALS. Specifically, this guidance addresses the FDA’s current thinking regarding the clinical development program and clinical trial design for drugs to support an indication for the treatment of ALS. Click here to read more.
